• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
75,273.45 1,205.00
( 1.63%)
Global Indices
Nasdaq
46,146.75 -82.73
(-0.18%)
Dow Jones
6,578.03 -23.97
(-0.36%)
Hang Seng
53,715.15 1,462.87
(2.80%)
Nikkei 225
10,078.37 113.21
(1.14%)
Forex
USD-INR
93.53 0.04
(0.04%)
EUR-INR
108.22 0.07
(0.07%)
GBP-INR
125.01 0.33
(0.27%)
JPY-INR
0.59 0.00
(0.23%)

EQUITY - MARKET SCREENER

Ajanta Pharma Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
532331
INE031B01049
330.3875196
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AJANTPHARM
37.92
35762.82
EPS(TTM)
Face Value()
Div & Yield %
75.48
2
0.98
 

hcl technologies ltd
Maruti Suzuki reports 12% YoY sales growth in January 2026
Feb 02,2026
Domestic passenger vehicle (PV) sales stood at 174,529 units, marginally higher by 0.5% YoY, while sales of light commercial vehicles (LCVs) declined 7.8% YoY to 3,771 units during the month.

While the company’s total domestic sales (PV+LCV+OEM) rose 0.4% YoY to 185,943 units, export sales, however, surged 88.3% YoY to 51,020 units, marking an all-time monthly high.

For the period from April to January of FY26, the company has registered total sales of 1,983,467 units, up 7.7% YoY.

Maruti Suzuki India is engaged in the manufacture, purchase, and sale of motor vehicles, components, and spare parts (automobiles).

The company reported a 4.08% YoY increase in net profit to Rs 3,879.1 crore in Q3 FY26, compared with Rs 3,726.9 crore in Q3 FY25, while revenue from operations rose 28.74% YoY to Rs 49,904.1 crore.

Shares of Maruti Suzuki India rose 0.31% to Rs 14,244.90 on the BSE.